Project Grant R44GM122095

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $676,629.27 to Wayne State University to develop a high-affinity carbon monoxide (CO) scavenger protein and a genetically encoded fluorescent CO reporter. The key objectives are to: 1) Utilize in vitro spectroscopic methods to identify the minimal functional CO-sensing hemoprotein domain and key residues conferring high CO affinity and...

This Project Grant award, valued at $1,267,716.00 and funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to investigate the role of red blood cells in stroke-related hyperglycemia. The key objectives of this multiple PI project are: 1) Characterizing acute hyperglycemia-related red blood cell alterations in clinical stroke patients, with a...

This $385,191 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to study the structure, function, and regulation of ATP-sensitive potassium (KATP) channels. The project aims to develop novel spectroscopic tools to simultaneously probe KATP channel structure and function, with the goal of understanding how ligand binding and long-range communication between subunits in the...

This $1,488,899 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the advanced development and validation of two novel therapeutic compounds, YT-002 and YT-004, to preserve myocardial tissue and function following myocardial infarction. The research aims to optimize the drug formulations, conduct detailed pharmacokinetic and pharmacodynamic studies, and perform comprehensive long-term safety...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $234,000.00 to the University of Colorado-Denver to engineer "hemostatic red blood cells" (T-RBCs) capable of adhering to collagen and fibrin clots. The goal is to develop a novel therapeutic approach to slow or stop non-compressible hemorrhage, which is a major cause of...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,223,140 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of Chicago to test a novel biopharmaceutical agent called Sanguinate for mitigating cerebral infarct growth in acute ischemic stroke. The objective is to evaluate Sanguinate's ability to boost arterial collateralization and deliver oxygen to ischemic brain tissue, with the goal of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $306,870 to Kinetiq Therapeutics LLC, a life science startup in Texas, to conduct proof-of-concept studies on an enzyme replacement therapy (ERT) for Fanconi anemia. Fanconi anemia is a rare inherited disease characterized by bone marrow failure and malignancies. The project aims to demonstrate the feasibility of using an...

This STTR Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $294,063 to Biomembretics, Inc. to develop and demonstrate a high-volume manufacturing technology for microfluidic oxygenators for extracorporeal membrane oxygenation (ECMO) to treat respiratory failure. The project aims to advance a bioinspired microfluidic oxygenator technology that can safely and effectively oxygenate blood, addressing limitations of the...

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $889,188 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a new oxygen therapy called intravenous oxygen (IVO2) for the early resuscitation of cardiac arrest patients. The IVO2 therapy utilizes pH-responsive polymeric microbubbles to deliver high...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $517,475 to the University of South Florida to develop novel small molecule compounds that can activate NAD+ for the treatment of heart failure. The key objectives are to utilize medicinal chemistry, structure-activity relationship modeling, and in vitro/ex vivo/in vivo testing to identify 1-2 lead P7C3-based small molecule...